Simvastatin enhances induction of inducible nitric oxide synthase in 3T3-L1 adipocytes

The present study was designed to determine whether hydroxymethylglutaryl-CoA reductase inhibitors (statins) modulate the NO production via iNOS in adipocytes stimulated by lipopolysaccharide (L) and tumour necrosis factor-α (T). Well-differentiated 3T3-L1 adipocytes significantly produced NO by LT-treatment. Pre-incubation with simvastatin, a lipophilic statin, pravastatin, a hydrophilic one, or Y27632, an inhibitor of Rho kinase, further enhanced the production of NO. The effect of simvastatin was offset by mevalonate and geranylgeranyl pyrophosphate (GGPP) but not by squalene. The mRNA level for iNOS parallelled the NO production. The NF-κB was activated by the LT-treatment and was further enhanced by simvastatin, pravastatin or Y27632 addition. Mevalonate and GGPP completely offset the effect of simvastatin. Statins and Y27632 also further increased the interleukin-6 secretion in the LT-treated 3T3-L1 adipocytes. These results suggest that statins, especially lipophilic type, enhance induction of iNOS by inhibiting the small GTP-binding protein signal in adipocytes.

[1]  A. Shirahata,et al.  N-acetylcysteine attenuates TNF-alpha induced changes in secretion of interleukin-6, plasminogen activator inhibitor-1 and adiponectin from 3T3-L1 adipocytes. , 2006, Life sciences.

[2]  M. Nakata,et al.  Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control , 2006, Diabetologia.

[3]  T. Yamakawa,et al.  Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus. , 2006, Journal of atherosclerosis and thrombosis.

[4]  K. Ichihara,et al.  HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats. , 2005, Biological & pharmaceutical bulletin.

[5]  R. Collins,et al.  Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). , 2005, Diabetes care.

[6]  N. Peng,et al.  Lovastatin reduces nuclear factor kappaB activation induced by C-reactive protein in human vascular endothelial cells. , 2005, Biological & pharmaceutical bulletin.

[7]  Young-Bum Kim,et al.  Role of Rho-kinase in regulation of insulin action and glucose homeostasis. , 2005, Cell metabolism.

[8]  D. Loskutoff,et al.  Molecular mechanisms of tumor necrosis factor‐α‐mediated plasminogen activator inhibitor‐1 expression in adipocytes , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  R. de Caterina,et al.  Simvastatin Attenuates Expression of Cytokine-inducible Nitric-oxide Synthase in Embryonic Cardiac Myoblasts* , 2005, Journal of Biological Chemistry.

[10]  Y. Hattori,et al.  RETRACTED: Statin blocks Rho/Rho-kinase signalling and disrupts the actin cytoskeleton: relationship to enhancement of LPS-mediated nitric oxide synthesis in vascular smooth muscle cells , 2004 .

[11]  T. Yano,et al.  Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors. , 2004, Biochemical pharmacology.

[12]  Y. Hattori,et al.  Statin blocks Rho/Rho-kinase signalling and disrupts the actin cytoskeleton: relationship to enhancement of LPS-mediated nitric oxide synthesis in vascular smooth muscle cells. , 2004, Biochimica et biophysica acta.

[13]  K. Ichihara,et al.  Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. , 2003, Biological and Pharmaceutical Bulletin.

[14]  Shailendra Giri,et al.  Rho A negatively regulates cytokine-mediated inducible nitric oxide synthase expression in brain-derived transformed cell lines: negative regulation of IKKalpha. , 2003, Free radical biology & medicine.

[15]  A. Shirahata,et al.  Differential effects of cyclic AMP on induction of nitric oxide synthase in 3T3-L1 cells and brown adipocytes. , 2003, Free radical biology & medicine.

[16]  Wan-Wan Lin,et al.  HMG-CoA reductase inhibitors inhibit inducible nitric oxide synthase gene expression in macrophages. , 2003, Journal of biomedical science.

[17]  B. Sobel,et al.  Intracellular signal transduction modulating expression of plasminogen activator inhibitor-1 in adipocytes. , 2003, Biochemical pharmacology.

[18]  A. Palazzuoli,et al.  Different effect induced by treatment with several statins on monocyte tissue factor expression in hypercholesterolemic subjects , 2003, Clinical and Experimental Medicine.

[19]  Y. Hattori,et al.  Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells. , 2002, Cardiovascular research.

[20]  L. Chamberlain.  Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3‐L1 adipocytes , 2001, FEBS letters.

[21]  R. Davidson,et al.  Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. , 2001, The American journal of cardiology.

[22]  P. Libby,et al.  An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In Vitro , 2001, Circulation.

[23]  Y. Deshaies,et al.  Nitric oxide: a new player in the modulation of energy metabolism , 2000, International Journal of Obesity.

[24]  K. Asayama,et al.  Troglitazone inhibits the expression of inducible nitric oxide synthase in adipocytes in vitro and in vivo study in 3T3-L1 cells and Otsuka Long-Evans Tokushima Fatty rats. , 2000, Life sciences.

[25]  M. Barbagallo,et al.  Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. , 2000, Atherosclerosis.

[26]  I. Tatsuno,et al.  Cell-anchorage, cell cytoskeleton, and Rho-GTPase family in regulation of cell cycle progression. , 2000, Progress in cell cycle research.

[27]  C. Dani,et al.  A role for preadipocytes as macrophage‐like cells , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  A. Namboodiri,et al.  N-acetyl cysteine inhibits induction of no production by endotoxin or cytokine stimulated rat peritoneal macrophages, C6 glial cells and astrocytes. , 1998, Free radical biology & medicine.

[29]  A. Namboodiri,et al.  Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. , 1997, The Journal of clinical investigation.

[30]  Y. Matsuzawa,et al.  Analysis of an expression profile of genes in the human adipose tissue. , 1997, Gene.

[31]  M. Karin,et al.  Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. , 1997, The New England journal of medicine.

[32]  D. Green,et al.  Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. , 1997, Circulation.

[33]  J. Salonen,et al.  Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. , 1995, Circulation.

[34]  S. Yap,et al.  Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types. , 1995, Biochimica et biophysica acta.

[35]  Carl Nathan,et al.  Nitric oxide synthases: Roles, tolls, and controls , 1994, Cell.

[36]  S. Padmaja,et al.  The reaction of no with superoxide. , 1993, Free radical research communications.

[37]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[38]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.